GlassScriptPhysician profile
John A Villanueva
NPI 1518134543
$2,706.15
in general payments reported to CMS, 2019-2025
23 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.84 · 2020: $209 · 2021: $353 · 2022: $197 · 2023: $280 · 2024: $556 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,549 · Travel and Lodging: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.46 |
| Travel and Lodging | $297.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $961.23 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Abbvie INC. | $430.69 | 2021-2025 | Ubrelvy, Qulipta |
| Vertex Pharmaceuticals Incorporated | $201.90 | 2024-2025 | |
| Medtronic, INC. | $149.78 | 2021-2025 | Intellis Adaptivestim, Accurian |
| Scilex Pharmaceuticals INC. | $138.66 | 2019-2021 | |
| Medtronic USA, INC. | $136.53 | 2020 | |
| Fidia Pharma USA INC. | $135.99 | 2022-2023 | Hymovis, Triluron |
| Allergan, INC. | $85.15 | 2021-2022 | |
| Forte Bio-Pharma LLC | $49.56 | 2023-2024 | Prolate, Nalocet |
| Stimwave Technologies Incorporated | $47.25 | 2020-2021 | |
| Horizon Therapeutics Plc | $43.22 | 2023 | Krystexxa |
| Konica Minolta Healthcare Americas, INC | $38.23 | 2019 | |
| Medline Industries LP | $33.90 | 2024-2025 | |
| Abbott Laboratories | $33.36 | 2020-2024 | Eterna |
| Stryker Corporation | $33.03 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $31.19 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spr Therapeutics, INC | $30.44 | 2024 | Sprint Pns System |
| Nalu Medical, INC. | $30.15 | 2024 | Nalu Neurostimulation System |
| Amgen INC. | $28.24 | 2024 | Krystexxa |
| Virtus Pharmaceuticals LLC | $20.55 | 2023 | Levorphanol Tartrate |
| Tersera Therapeutics LLC | $20.10 | 2024 | Prialt |
| Glaxosmithkline, LLC. | $14.84 | 2024 | Shingrix |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Villanueva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.